Healthcare
Live Price
Offline$44.38
+1.84% today
1Y Change
+35.01%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Supernus Pharmaceuticals, Inc. (SUPN) is a Healthcare stock with a market cap of $2.76B and listed on NASDAQ. The stock last traded around $44.38 and up 35.0% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of -150.7%, a dividend yield of 0.0%. What stands out right now is revenue +8.6%, EPS -150.7%, free cash flow -73.1% with operating margin -6.2% and ROIC -3.1%. Valuation is more restrained than many high-expectation growth names at price/sales 3.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SUPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SUPN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SUPN Max Drawdown
-23.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SUPN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$579.8M
-13.1% YoY
FY Net Income
$53.4M
-12.0% YoY
Free Cash Flow
$125.1M
+7.4% YoY
Revenue Growth
+8.6%
EPS Growth
-150.7%
Gross Margin
85.5%
Net Margin
-5.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 719M | 662M | 608M | 667M | 580M |
| Gross Profit | 644M | 584M | 524M | 580M | 505M |
| Operating Income | -37M | 82M | -5M | 46M | 86M |
| EBITDA | 41M | 178M | 90M | 153M | 129M |
| Net Income | -39M | 74M | 1M | 61M | 53M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 128M | 69M | 75M | 93M | 203M |
| Total Assets | 1.5B | 1.4B | 1.3B | 1.7B | 1.7B |
| Total Liabilities | 391M | 332M | 356M | 816M | 873M |
| Shareholder Equity | 1.1B | 1.0B | 922M | 886M | 816M |
| Total Debt | 41M | 34M | 42M | 445M | 427M |
| Net Debt | -87M | -35M | -34M | 352M | 224M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
127M
+8.8% YoY
Capital Expenditures
2M
-396.4% YoY
Free Cash Flow
125M
+7.4% YoY
Key ratios
Gross Margin
85.5%
Operating Margin
-6.2%
Net Margin
-5.4%
ROE
-3.7%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.